

# **Product** Data Sheet

# (Aminooxy)acetamide-Val-Cit-PAB-MMAE

 Cat. No.:
 HY-153263 

 CAS No.:
 2446645-88-9 

 Molecular Formula:
  $C_{60}H_{97}N_{11}O_{14}$  

 Molecular Weight:
 1196.48 


Target: Drug-Linker Conjugates for ADC

Pathway: Antibody-drug Conjugate/ADC Related

Storage: -20°C, sealed storage, away from moisture and light

\* In solvent: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture

and light)



### **SOLVENT & SOLUBILITY**

#### In Vitro

DMSO: 100 mg/mL (83.58 mM; Need ultrasonic)

Preparing Stock Solutions	Solvent Mass Concentration	1 mg	5 mg	10 mg
	1 mM	0.8358 mL	4.1789 mL	8.3578 mL
	5 mM	0.1672 mL	0.8358 mL	1.6716 mL
	10 mM	0.0836 mL	0.4179 mL	0.8358 mL

Please refer to the solubility information to select the appropriate solvent.

In Vivo

- 1. Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline Solubility: ≥ 2.5 mg/mL (2.09 mM); Clear solution
- 2. Add each solvent one by one: 10% DMSO >> 90% (20% SBE-β-CD in saline) Solubility: ≥ 2.5 mg/mL (2.09 mM); Clear solution
- 3. Add each solvent one by one: 10% DMSO >> 90% corn oil Solubility: ≥ 2.5 mg/mL (2.09 mM); Clear solution

## BIOLOGICAL ACTIVITY

Description

(Aminooxy)acetamide-Val-Cit-PAB-MMAE (MMAE 5) is an intermediate used in the synthetic preparation of drug-linker conjugates for ADC. (Aminooxy)acetamide-Val-Cit-PAB-MMAE is conjugated to polyamide via oxime bond formation to form MMAE polyamide conjugate. Then MMAE polyamide conjugate can be conjugated to Trastuzumab, to make ADC<sup>[1]</sup>.

## **REFERENCES**

[1]. Ouberai Myriam, et al. Prepa 25.	aration of antibody-drug conju	igates using polymers and crossli	nkers. World Intellectual Property Organi	zation, WO2020128488 A1. 2020-06-
			cal applications. For research use or	
	Tel: 609-228-6898 Address: 1 D	Fax: 609-228-5909 eer Park Dr, Suite Q, Monmout	E-mail: tech@MedChemExpress.co th Junction, NJ 08852, USA	om

Page 2 of 2 www.MedChemExpress.com